Effectiveness of Suprachoroidal Injection of Triamcinolone Acetonide in Diabetic Macular Edema Following Pars Plana Vitrectomy Using a Modified Custom Microneedle

References

• Sarao V, Veritti D, Boscia F, Lanzetta P. Intravitreal steroids for the treatment of retinal diseases. Sci World J. 2014;2014:1–14. doi:10.1155/2014/989501
   Google Scholar
• Daruich A, Matet A, Moulin A, et al.. Mechanisms of macular edema: beyond the surface. Prog Retin Eye. research. 2018;63:20–68‏. doi:10.1016/j.preteyeres.2017.10.006
   PubMed Web of Science ®Google Scholar
• Sacconi R, Giuffrè C, Corbelli E, Borrelli E, Querques G, Bandello F. Emerging therapies in the management of macular edema: a review. F1000Res. 2019;12(8):F1000 Faculty Rev–1413. doi:10.12688/f1000research.19198.1
   Google Scholar
• Gupta V, Arevalo JF. Surgical management of diabetic retinopathy. Middle East Afr J Ophthalmol. 2013;20(4):283. doi:10.4103/0974-9233.120003
   PubMedGoogle Scholar
• Todorich B, Mahmoud TH. Vitrectomy for diabetic macular edema. Curr Ophthalmol Rep. 2014;2:167–174. doi:10.1007/s40135-014-0052-6
   Google Scholar
• White NH, Sun W, Cleary PA, Tamborlane WV, Danis RP, Dp& H. DCCT-EDIC Research Group. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes. 2010;59(5):1244–1253. doi:10.2337/db09-1216
   PubMed Web of Science ®Google Scholar
• Frisina R, Pinackatt SJ, Sartore M, et al. Cystoid macular edema after pars plana vitrectomy for idiopathic epiretinal membrane. Graefes Arch Clin Exp Ophthalmol. 2015;253:47–56. doi:10.1007/s00417-014-2655-x
   PubMed Web of Science ®Google Scholar
• de Smet MD. Insights into the physiopathology of inflammatory macular edema. Dev Ophthalmol. 2017;58:168–177. doi:10.1159/000455279
   PubMedGoogle Scholar
• Heier JS, Korobelnik JF, Brown DM, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the Vista and VIVID studies. Ophthalmology. 2016;123(11):2376–2385. doi:10.1016/j.ophtha.2016.07.032
   PubMed Web of Science ®Google Scholar
• Crim N, Velez-Montoya R, Morales-Canton V. Surgical Versus Medical Treatment for Diabetic Macular Edema: a Review. Med Hypothesis Discov Innov Ophthalmol. 2017;6(4):136–142. PMID: 29560368; PMCID: PMC5847309.
   PubMedGoogle Scholar
• Yanyali A, Aytug B, Horozoglu F, Nohutcu AF. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. A J. ophthalmology. 2007;144(1):124–126. doi:10.1016/j.ajo.2007.02.048
   Google Scholar
• Boyer DS, Faber D, Gupta S, Patel SS, Tabandeh H, Ozurdex CHAMPLAIN Study Group LXY&. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 2011;31(5):915–923. doi:10.1097/IAE.0b013e318206d18c
   PubMed Web of Science ®Google Scholar
• Comyn O, Lightman SL, Hykin PG. Corticosteroid intravitreal implants vs. ranibizumab for the treatment of vitreoretinal disease. Curr Opin Ophthalmol. 2013;24(3):248–254. doi:10.1097/ICU.0b013e32835fab27
   PubMed Web of Science ®Google Scholar
• Arcinue CA, Ceron OM, Foster CS. A comparison between the fluocinolone acetonide (retisert) and dexamethasone (ozurdex) intravitreal implants in uveitis. J Ocul Pharmacol Ther. 2013;29(5):501–507. doi:10.1089/jop.2012.0180
   PubMed Web of Science ®Google Scholar
• Naftali Ben Haim L, Moisseiev E. Drug delivery via the suprachoroidal space for the treatment of retinal diseases. Pharmaceutics. 2021;13(7):967. doi:10.3390/pharmaceutics13070967
   PubMed Web of Science ®Google Scholar
• Hartman RR, Kompella UB. Intravitreal, subretinal, and suprachoroidal injections: evolution of microneedles for drug delivery. J Ocul Pharmacol Ther. 2018;34(1–2):141–153. doi:10.1089/jop.2017.0121
   PubMed Web of Science ®Google Scholar
• Patel SR, Berezovsky DE, McCarey BE, Zarnitsyn V, Edelhauser HF, Prausnitz MR. Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye. Invest Ophthalmol Vis Sci. 2012;53(8):4433–4441. doi:10.1167/iovs.12-9872
   PubMed Web of Science ®Google Scholar
• Hancock SE, Wan CR, Fisher NE, Andino RV, Ciulla TA. Biomechanics of suprachoroidal drug delivery: from benchtop to clinical investigation in ocular therapies. Expert Opin Drug Deliv. 2021;18(6):777–788. doi:10.1080/17425247.2021.1867532
   PubMed Web of Science ®Google Scholar
• Goldstein DA, Do D, Noronha G, Kissner JM, Srivastava SK, Nguyen QD. Suprachoroidal corticosteroid administration: a novel route for local treatment of noninfectious uveitis. Transl Vis Sci Technol. 2016;5(6):14. doi:10.1167/tvst.5.6.14
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Wykoff CC, Brown DM, et al. Suprachoroidal triamcinolone acetonide for retinal vein occlusion: results of the tanzanite study. Ophthalmol Retina. 2018;2(4):320–328. doi:10.1016/j.oret.2017.07.013
   PubMedGoogle Scholar
• Nawar AE. Modified microneedle for suprachoroidal injection of triamcinolone acetonide combined with intravitreal injection of ranibizumab in branch retinal vein occlusion patients. Clin Ophthalmol. 2022;1139–1151‏. doi:10.2147/OPTH.S361636
   PubMed Web of Science ®Google Scholar
• Nawar AE. Effectiveness of suprachoroidal injection of triamcinolone acetonide in resistant diabetic macular edema using a modified microneedle. Clin Ophthalmol. 2022;3821–3831‏. doi:10.2147/OPTH.S391319
   PubMed Web of Science ®Google Scholar
• Zhang DD, Che DY, Zhu DQ. A simple technique for suprachoroidal space injection of triamcinolone acetonide in treatment of macular edema. Int J Ophthalmol. 2022;15(12):2017. doi:10.18240/ijo.2022.12.18
   PubMed Web of Science ®Google Scholar
• Templeton GF. A two-step approach for transforming continuous variables to normal: implications and recommendations for IS research. Commun Assoc Inf Syst. 2011;28(1):4. doi:10.17705/1CAIS.02804
   Google Scholar
• Chiang B, Jung JH, Prausnitz MR. The suprachoroidal space as a route of administration to the posterior segment of the eye. Adv Drug Deliv Rev. 2018;126:58–66. doi:10.1016/j.addr.2018.03.001
   PubMed Web of Science ®Google Scholar
• Habot-Wilner Z, Noronha G, Wykoff CC. Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach. Acta Ophthalmol. 2019;97(5):460–472. doi:10.1111/aos.14042
   PubMed Web of Science ®Google Scholar
• Abarca BC, EM SJH, Patel S, Patel S. Treatment of acute posterior uveitis in a porcine model by injection of triamcinolone acetonide into the suprachoroidal space using microneedles. Invest Ophthalmol Vis Sci. 2013;54(4):2483–2492. doi:10.1167/iovs.13-11747
   PubMed Web of Science ®Google Scholar
• Price KW, Albini TA, Yeh S. Suprachoroidal injection of triamcinolone- Review of a novel treatment for macular edema caused by noninfectious uveitis. US Ophthalmic Rev. 2020;13(2):76–79. doi:10.17925/usor.2020.13.2.76
   PubMedGoogle Scholar
• Oli A, Waikar S. Modified inexpensive needle for suprachoroidal triamcinolone acetonide injections in pseudophakic cystoid macular edema. Indian J Ophthalmol. 2021;69(3):765. doi:10.4103/ijo.IJO_1464_20
   PubMed Web of Science ®Google Scholar
• Jung SM, JW PSW, Lee JE, Byon IS, Byon IS. Retinal injury following intravitreal injection of a dexamethasone implant in a vitrectomized eye. Int J Ophthalmol. 2017;10(6):1019–1020. doi:10.18240/ijo.2017.06.31
   PubMed Web of Science ®Google Scholar
• Marashi A, Zazo A. Suprachoroidal injection of triamcinolone acetonide using a custom-made needle to treat diabetic macular edema post pars plana vitrectomy: a case series. J Int Med Res. 2022;50(4). doi:10.1177/03000605221089807
   PubMed Web of Science ®Google Scholar
• Abdelshafy Tabl A, Tawfik Soliman T, Anany Elsayed M, Abdelshafy Tabl M, Meduri A. A randomized trial comparing suprachoroidal and intravitreal injection of triamcinolone acetonide in refractory diabetic macular edema due to epiretinal membrane. J Ophthalmol. 2022. doi:10.1155/2022/7947710
   PubMed Web of Science ®Google Scholar
• Özdemir HB, Hasanreisoğlu M, Yüksel M, Ertop M, Gürelik G, Özdek Ş. Effectiveness of intravitreal dexamethasone implant treatment for diabetic macular edema in vitrectomized eyes. Turk J Ophthalmol. 2019;49(6):323. doi:10.4274/tjo.galenos.2019.95226
   PubMedGoogle Scholar
• Nawar AE, Wasfy T, Shafik HM. Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection. BMC Ophthalmol. 2022;22(1):1–10. doi:10.1186/s12886-022-02503-x
   PubMed Web of Science ®Google Scholar
• Mastropasqua R, Toto L, Borrelli E, et al. Morphology and function over a one-year follow up period after intravitreal dexamethasone implant (Ozurdex) in patients with diabetic macular edema. PLoS One. 2015;10(12):e0145663. doi:10.1371/journal.pone.0145663
   PubMed Web of Science ®Google Scholar
• Karttunen T, Nummelin L, Kaarniranta K, Kinnunen K. Real life experience of dexamethasone implant in refractory diabetic macular oedema. Clin Ophthalmol. 2019;13:2583–2590. doi:10.2147/OPTH.S232549
   PubMed Web of Science ®Google Scholar
• Cao J, You K, Jin K, et al. Prediction of response to anti-vascular endothelial growth factor treatment in diabetic macular oedema using an optical coherence tomography-based machine learning method. Acta Ophthalmol. 2020;99(1):e19–e27. doi:10.1111/aos.14514
   PubMed Web of Science ®Google Scholar
• Meduri A, Oliverio GW, Trombetta L, Giordano M, Inferrera L, Trombetta CJ. Optical coherence tomography predictors of favorable functional response in naïve diabetic macular edema eyes treated with dexamethasone implants as a first-line agent. J Ophthalmol. 2021;2021:1–5. doi:10.1155/2021/6639418
   Web of Science ®Google Scholar
• Wu L, Chawan-Saad J, Wu M, Wu A. Corticosteroids for diabetic macular edema. Taiwan J Ophthalmol. 2019;9(4):233–242. doi:10.4103/tjo.tjo_68_19
   PubMedGoogle Scholar
• Early Treatment Diabetic Retinopathy Study Research Group Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early treatment diabetic retinopathy study report number 2. Ophthalmology. 1987;94(7):761–774. doi:10.1016/S0161-6420(87)33527-4.
   PubMed Web of Science ®Google Scholar
• Hatz K, Ebneter A, Tuerksever C, Pruente C, Zinkernagel M. Repeated dexamethasone intravitreal implant for the treatment of diabetic macular oedema unresponsive to anti-VEGF Therapy: Outcome and Predictive SD-OCT Features. Ophthalmologica. 2018;239(4):205–214. doi:10.1159/000485852
   PubMed Web of Science ®Google Scholar
• Barthelmes D, Sutter FK, Gillies MC. Differential optical densities of intraretinal spaces. Investig Ophthalmol Vis Sci. 2008;49(8):3529–3534. doi:10.1167/iovs.07-1320
   PubMed Web of Science ®Google Scholar
• Muftuoglu IK, Mendoza N, Gaber R, Alam M, You QS, Freeman WR. Integrity of outer retinal layers after resolution of central involved diabetic macular edema. Retina. 2017;37(11):2015–2024. doi:10.1097/IAE.0000000000001459
   PubMed Web of Science ®Google Scholar
• Rangaraju L, Jiang X, McAnany JJ, et al. Association between visual acuity and retinal layer metrics in diabetics with and without macular edema. J Ophthalmol. 2018;2018:1–8. doi:10.1155/2018/1089043
   Web of Science ®Google Scholar
• Channa R, Sophie R, Khwaja AA, et al. Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab. Eye (Lond). 2014;28(3):269–278. doi:10.1038/eye.2013.245
   PubMed Web of Science ®Google Scholar
• Eski Yucel O, Birinci H, Sullu Y. Outcome and predictors for 2-year visual acuity in eyes with diabetic macular edema treated with Ranibizumab. J Ocul Pharmacol Ther. 2019;35(4):229–234. doi:10.1089/jop.2018.0082
   PubMed Web of Science ®Google Scholar
• Sophie R, Lu N, Campochiaro PA. Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with Ranibizumab. Ophthalmology. 2015;122(7):1395–1401. doi:10.1016/j.ophtha.2015.02.036
   PubMed Web of Science ®Google Scholar